Digital PCR in Oncology Applications

combinati-selects-2-150

Oncology research using dPCR delivers the most accurate results

Applications for digital PCR in oncology are myriad, from biomarker discovery to early detection, liquid biopsy research as well as monitoring recurrence and response to treatment. For all applications in translational cancer research, the Absolute Q digital PCR platform brings 4-color multiplexing capabilities, improved sensitivity, and a one-step, walkaway workflow to your application.

Rare target quantification in liquid biopsy

Identifying oncogenic mutations via liquid biopsy can be used for early detection, measuring therapeutic response, quantifying residual disease, and monitoring emerging resistance to targeted therapies. Here, we demonstrate compatibility with Applied Biosystems™ TaqMan™ Liquid Biopsy assays, performing robust detection of 5 different hotspot mutations down to 0.1% allelic frequency. See the TaqMan protocol here.

Precision cancer monitoring

In this publication in Scientific Reports, Combinati shows the capability of the Absolute Q to to detect and quantify non-small cell lung carcinoma (NSCLC) rare genetic mutants (EGFR T790M) with precision cell-free DNA (cfDNA) standards.

Sensitive and precise detection of treatment-relevant cancer mutations with an existing 2-enzyme PCR chemistry

Tyrosine kinase inhibitors are a cornerstone of precision medicine and are a standard of care for those harboring oncogenic mutations. Unfortunately, drug-resistant mutations are a common result of this treatment. Sensitive and precise detection of these variants are critical to make well-informed treatment decisions. See how the Absolute Q was used alongside an existing two-enzyme PCR chemistry to enable highly precise interrogation of challenging genomic regions, identifying EGFR pT790M mutations down to 5 copies per reaction – all without the need for a standard curve.

 

Luminex & Absolute Q

Luminex uses the Combinati Absolute Q platform to identify underlying mechanisms of drug resistance in metastatic breast cancer with Luminex multiplex PCR chemistry.

Highlights of this webinar include:

  • Introduction to Microfluidic Array Partitioning (MAP) technology for digital PCR
  • Demonstration of a multiplex assay to identify and quantify 11 single nucleotide polymorphisms (SNPs) within the ESR1 gene in a single sample
  • Utility of using the Absolute Q, a 4-color digital PCR platform with a walkaway workflow, in translational oncology research

Ready to learn more?

Find out more about harnessing the
power of Digital PCR for your research.